Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Unicycive Therapeutics, Inc. (UNCY : NSDQ)

• Company Description    Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $3.89 Daily Weekly Monthly 20 Day Moving Average: 1,055,401 shares Shares Outstanding: 27.85 (millions) Market Capitalization: $108.36 (millions) Beta: 1.83 52 Week High: $8.74 52 Week Low: $3.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.13% -18.27% 12 Week -26.60% -28.40% Year To Date -32.58% -39.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1975 W. EL CAMINO REAL SUITE 204 - MOUNTAIN VIEW,CA 94040 USA ph: 650-351-4495 fax: - ir@unicycive.com http://www.unicycive.com

• General Corporate Information    Officers Shalabh Gupta - Chief Executive Officer; President and Chairman John Townsend - Chief Financial Officer Sandeep Laumas - Director Saraswati Kenkare-Mitra - Director Gaurav Aggarwal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 90466Y202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 27.85 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.83 Market Capitalization: $108.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.00 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 88.46% vs. Previous Quarter: 88.89% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -91.50 03/31/26 - -134.69 ROA 09/30/26 - - 06/30/26 - -61.47 03/31/26 - -84.51 Current Ratio 09/30/26 - - 06/30/26 - 3.81 03/31/26 - 2.40 Quick Ratio 09/30/26 - - 06/30/26 - 3.81 03/31/26 - 2.40 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 1.94 03/31/26 - 1.41 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©